Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | PRKCA | P17252 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10144997 | 1.00 | ALOX5 (0.60) | ALOX5ALDH1A1KDM4EMEN1GAA | |
| SCHEMBL8698788 | 0.87 | PLOD2 (0.56) | ALOX5ALDH1A1MEN1KMT2AATM | |
| SCHEMBL8698430 | 0.86 | KMO (0.63) | ALOX5ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL16595437 | 0.86 | ALDH1A1 (0.56) | ALOX5ALDH1A1KDM4EMEN1GAA | |
| SCHEMBL2306348 | 0.86 | ALOX5 (0.58) | ALOX5ALDH1A1ATMSMN1; SMN2LMNA | |
| SCHEMBL13598421 | 0.85 | ALOX5 (0.55) | ALOX5ALDH1A1KDM4EMEN1GAA | |
| SCHEMBL14881542 | 0.85 | ALOX5 (0.56) | ALOX5ALDH1A1MEN1HPGDKMT2A | |
| SCHEMBL242325 | 0.85 | ATM (0.57) | ALOX5ALDH1A1MEN1KMT2AATM | |
| SCHEMBL6507440 | 0.85 | ATM (0.57) | ALOX5ALDH1A1ATMSMN1; SMN2LMNA | |
| SCHEMBL6011450 | 0.85 | ALDH1A1 (0.56) | ALOX5ALDH1A1MEN1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234355-A1 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-09-16 | — | — | US | disclosed |
| CN-101506171-A | Isoquinoline derivatives as inhibitors of cytokine mediated diseases and uses thereof | ASTRAZENECA AB (SE) | 2009-08-12 | — | — | CN | disclosed |
| EP-2035386-A1 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASES | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| US-20080207596-A1 | Novel compounds 329 | MARTIN BARRIE | 2008-08-28 | — | — | US | disclosed |
| WO-2007149031-A1 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207596-A1 | Novel compounds 329 | CCL11, IL2, IL1B | ALOX5 2399/4885ALDH1A1 974/4885KDM4E 3798/4885 |
| US-20100234355-A1 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASES | IL2, IFNG, IL1B | ALOX5 2021/4885ALDH1A1 808/4885KDM4E 3956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.